Bausch Health Companies Inc (BHC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bausch Health Companies Inc stock (BHC) is currently trading at $5.08. Bausch Health Companies Inc PE ratio is 11.88. Bausch Health Companies Inc PS ratio (Price-to-Sales) is 0.18. Analyst consensus price target for BHC is $7.71. WallStSmart rates BHC as Moderate Buy.
- BHC PE ratio analysis and historical PE chart
- BHC PS ratio (Price-to-Sales) history and trend
- BHC intrinsic value — DCF, Graham Number, EPV models
- BHC stock price prediction 2025 2026 2027 2028 2029 2030
- BHC fair value vs current price
- BHC insider transactions and insider buying
- Is BHC undervalued or overvalued?
- Bausch Health Companies Inc financial analysis — revenue, earnings, cash flow
- BHC Piotroski F-Score and Altman Z-Score
- BHC analyst price target and Smart Rating
Bausch Health Companies Inc
📊 No data available
Try selecting a different time range
BHC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Bausch Health Companies Inc (BHC)
BHC trades at a significant discount to its Graham intrinsic value of $19.66, offering a 69% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Bausch Health Companies Inc (BHC) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, return on equity, operating margin. Concerns around price/book and profit margin. Overall metrics suggest strong investment potential with favorable risk/reward.
Bausch Health Companies Inc (BHC) Key Strengths (6)
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $44 in profit
Paying less than $1 for every $1 of annual revenue
Earnings per share surging 1368.00% year-over-year
Strong operational efficiency: $26 kept per $100 revenue
66.21% held by institutions, strong professional interest
Supporting Valuation Data
Bausch Health Companies Inc (BHC) Areas to Watch (4)
Very expensive at 18.8x book value
Very thin margins, barely profitable
Modest revenue growth at 9.30%
Small-cap company with higher risk but more growth potential
Bausch Health Companies Inc (BHC) Detailed Analysis Report
Overall Assessment
This company scores 69/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.3/10) while 4 fall into concern territory (avg 3.3/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Return on Equity, Price/Sales. Valuation metrics including PEG Ratio (0.01), Price/Sales (0.18) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 43.60%, Operating Margin at 25.80%. Growth metrics are encouraging with EPS Growth at 1368.00%.
The Bear Case
The primary concerns are Price/Book, Profit Margin, Revenue Growth. Some valuation metrics including Price/Book (18.78) suggest expensive pricing. Growth concerns include Revenue Growth at 9.30%, which may limit upside. Profitability pressure is visible in Profit Margin at 1.53%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 43.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 9.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Return on Equity) and negatives (Price/Book, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BHC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BHC's Price-to-Sales ratio of 0.18x trades at a deep discount to its historical average of 3.63x (0th percentile). The current valuation is 98% below its historical high of 11.48x set in Apr 2011, and 0% above its historical low of 0.18x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bausch Health Companies Inc (BHC) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Bausch Health Companies Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 10.3B with 9% growth year-over-year. Profit margins are thin at 1.5%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 43.6% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 403M in free cash flow and 496M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Bausch Health Companies Inc push profit margins above 15% as the business scales?
Debt management: total debt of 21.2B is significantly higher than cash (1.3B). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Bausch Health Companies Inc.
Bottom Line
Bausch Health Companies Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bausch Health Companies Inc(BHC)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company is headquartered in Laval, Canada.